(Q34513371)

2 August 2017

Combined treatment with interferon-alpha and ribavirin for subacute sclerosing panencephalitis (English)

1 reference

2 August 2017

1 reference

Tomoda A

1

1 reference

2 August 2017

Shiraishi S

2

1 reference

2 August 2017

Hosoya M

3

1 reference

2 August 2017

Hamada A

4

1 reference

2 August 2017

Miike T

5

1 reference

2 August 2017

1 January 2001

1 reference

2 August 2017

1 reference

2 August 2017

24

1 reference

2 August 2017

54-59

1 reference

2 August 2017

1

1 reference

Subacute sclerosing panencephalitis and chorioretinitis

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900233-2

7 January 2021

Augmentation by interferon of human natural and antibody-dependent cell-mediated cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900233-2

7 January 2021

Broad-spectrum synergistic antiviral activity of selenazofurin and ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900233-2

7 January 2021

Long-term follow-up of patients with subacute sclerosing panencephalitis treated with intraventricular alpha-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900233-2

7 January 2021

Alpha-interferon and isoprinosine in adult-onset subacute sclerosing panencephalitis

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900233-2

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900233-2

7 January 2021

The cooperative effect of interferon-alpha and ribavirin on subacute sclerosing panencephalitis (SSPE) virus infections, in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900233-2

7 January 2021

Long-term follow-up of patients with subacute sclerosing panencephalitis treated with inosiplex

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900233-2

7 January 2021

Effect of ribavirin on subacute sclerosing panencephalitis virus infections in hamsters

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900233-2

7 January 2021

Oral ribavirin therapy for subacute sclerosing panencephalitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900233-2

7 January 2021

Successful treatment of disseminated measles in a patient with acquired immunodeficiency syndrome: consideration of antiviral and passive immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900233-2

7 January 2021

Subacute measles encephalitis in the young immunocompromised host: report of two cases diagnosed by polymerase chain reaction and treated with ribavirin and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900233-2

7 January 2021

Treatment of severe La Crosse encephalitis with intravenous ribavirin following diagnosis by brain biopsy

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2800%2900233-2

7 January 2021

10.1016/S0887-8994(00)00233-2

Identifiers

DOI

1 reference

2 August 2017

1 reference